RENAL ULTRASOUND SYSTEM MARKET

INTRODUCTIONRENAL ULTRASOUND SYSTEM MARKET

State-of-the-art renal ultrasonography equipment is an innovative medical tool for the precise diagnosis and management of kidney-related disorders.

This device, which is outfitted with cutting-edge features and technology, offers a non-invasive technique to evaluate the kidneys and surrounding structures in real-time, giving professionals important information for making wise judgements.

Medical practitioners may see the kidneys, assess their size and form, and find any anomalies or obstructions that might be compromising their function with our renal ultrasound equipment. The method can also be used to guide operations like kidney biopsies or drainage procedures and track the efficacy of therapies.

This system is user-friendly, adaptable, and trustworthy, making it an essential tool for nephrologists, urologists, and other medical specialists caring for patients with kidney disease.

RENAL ULTRASOUND SYSTEM MARKETSIZE AND FORECAST

 TheGlobal Renal ultrasound system marketaccounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

RENAL ULTRASOUND SYSTEM MARKETNEW PRODUCT LAUNCH

ReCor Medical Inc., an Otsuka Medical Devices Co. Ltd. wholly owned company, has released the Paradise Ultrasound Renal Denervation System in Germany to treat uncontrolled hypertension. Heart Centre Leipzig and Saarland University Hospital, Homburg/Saar, were the first to commercialise the treatment.

Paradise ultrasonography renal denervation is a minimally invasive, device-based therapy for the treatment of high blood pressure. The Paradise catheter is inserted into the renal artery during the surgery, which normally takes less than an hour.

Typically, three short bursts of ultrasound energy are delivered to each of the principal arteries going to the kidneys. Ultrasound emissions denervate the renal neurons and reduce sympathetic nervous system activity, resulting in reduced blood pressure.

In the United States, the Paradise System is classified as an experimental device. ReCor is now performing a crucial IDE pivotal research (RADIANCE-II) in patients with uncontrolled hypertension in the United States.

ReCor Medical, based in Palo Alto, California, is a medical technology firm dedicated on changing the management of hypertension, the world's leading cardiovascular risk factor.

ReCor pioneered the minimally invasive use of ultrasonography in renal denervation to treat hypertension patients with its Paradise System. In the United States, the Paradise System is classified as an experimental device. It is CE marked and approved for sale in the EU. 

RENAL ULTRASOUND SYSTEM MARKETCOMPANY PROFILE

• GE Healthcare
• Philips Healthcare
• Siemens Healthineers
• Hitachi Healthcare
• Toshiba Medical Systems 

THISRENAL ULTRASOUND SYSTEM MARKETREPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Renal ultrasound Systems are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Renal ultrasound System and key vendor selection criteria
3. Where is the Renal ultrasound System manufactured? What is the average margin per unit?
4. Market share of Global Renal ultrasound System market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Renal ultrasound System in-house
6. key predictions for next 5 years in Global Renal ultrasound System market
7. Average B-2-B Renal ultrasound System market price in all segments
8. Latest trends in Renal ultrasound System market, by every market segment
9. The market size (both volume and value) of the Renal ultrasound System market in 2024-2030 and every year in between?
10. Production breakup of Renal ultrasound System market, by suppliers and their OEM relationship